Acrivastina

Acrivastina Uses, Dosage, Side Effects, Food Interaction and all others data.

Acrivastina is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia.

Acrivastina is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D.

Trade Name Acrivastina
Availability Unknown
Generic Acrivastine
Acrivastine Other Names acrivastina, Acrivastine
Type
Formula C22H24N2O2
Weight Average: 348.4382
Monoisotopic: 348.183778022
Protein binding

Acrivastine binding to human plasma proteins was 50 ± 2.0%.

Groups Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Acrivastina
Acrivastina

Uses

Acrivastina is an antihistamine agent used for the symptomatic relief of seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.

For the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion.

Acrivastina is also used to associated treatment for these conditions: Seasonal Allergic Rhinitis

Food Interaction

No interactions found.

Acrivastina Alcohol interaction

[Moderate] GENERALLY AVOID:

Alcohol may potentiate some of the pharmacologic effects of central nervous system (CNS)-active agents.

Use in combination may result in additive CNS depression and/or impairment of judgment, thinking, and psychomotor skills.

Patients receiving CNS-active agents should be advised to avoid or limit consumption of alcohol.

Ambulatory patients should be counseled against driving, operating machinery, or engaging in potentially hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

Volume of Distribution

0.46 ± 0.05 L/kg

Elimination Route

Acrivastina was absorbed rapidly from the combination capsule following oral administration and was as bioavailable as a solution of acrivastine. After administration of SEMPREX-D Capsules, maximum plasma acrivastine concentrations were achieved at 1.14 ± 0.23 hour.

Half Life

The mean terminal half-life for acrivastine was 1.9 ± 0.3 hours following single oral doses and increased to 3.5 ± 1.9 hours at steady state. The terminal half-life for the propionic acid metabolite was 3.8 ± 1.4 hours.

Clearance

2.9 ± 0.7 mL/min/kg

Elimination Route

A mass balance study in 7 healthy volunteers showed that acrivastine is primarily eliminated by the kidneys. Over a 72-hour collection period, about 84% of the administered total radioactivity was recovered in urine and about 13% in feces, for a combined recovery of about 97%.

Innovators Monograph

You find simplified version here Acrivastina

*** Taking medicines without doctor's advice can cause long-term problems.
Share